Literature DB >> 19418113

Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients.

Inês Esteves Baldeiras1, Maria Helena Ribeiro, Paula Pacheco, Alvaro Machado, Isabel Santana, Luís Cunha, Catarina Resende Oliveira.   

Abstract

The clinical diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD) is difficult, and reliable markers are highly desired. In this work we assess the value of several cerebrospinal fluid (CSF) markers for sCJD diagnosis. Within the framework of the Portuguese Epidemiological Surveillance Program for Human Prion Diseases, CSF samples from 71 patients with clinically suspected sCJD, 30 definite sCJD and 41 non-CJD patients, were analysed for the presence of 14-3-3 protein. CSF levels of tau (t-tau), and phosphorylated tau (p-tau181), S-100b and beta amyloid (Abeta42) proteins were determined. The influence of clinical and genetic characteristics on CSF markers sensitivity was also evaluated. Protein 14-3-3 was detected in 29/30 sCJD patients and 9/41 non-CJD patients. Extremely elevated t-tau and S-100b protein levels were found in sCJD patients, while p-tau181 levels were only slightly elevated and Abeta42 showed no differences compared to controls. 14-3-3 was the most sensitive parameter (97%), but its specificity was low (78%); sensitivity/specificity for other proteins were: S-100b-93/93%, t-tau-93/95%, with maximum accuracy being obtained by a combination of tests (14-3-3 combined with either t-tau or S-100b, or combining S-100b with t-tau/Abeta42 or p-tau/t-tau ratios). The sensitivity of 14-3-3, as well as of p-tau181/t-tau ratio, was decreased in younger patients with long disease duration, with the PrP-2 isotype and MV genotype. Both 14-3-3, t-tau and S-100b are sensitive markers for sCJD, but 14-3-3 specificity seems to be lower in this special clinical setting of rapidly progressing dementias. We propose that in cases with a 14-3-3 weak positive result, or in young patients with long disease duration, a second CSF marker would be valuable for the diagnosis of sCJD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19418113     DOI: 10.1007/s00415-009-5160-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  43 in total

Review 1.  Clinical and laboratory diagnosis of Creutzfeldt-Jakob disease.

Authors:  T Weber
Journal:  Clin Neuropathol       Date:  2000 Sep-Oct       Impact factor: 1.368

Review 2.  Laboratory diagnosis of variant Creutzfeldt-Jakob disease.

Authors:  J W Ironside; M W Head; J E Bell; L McCardle; R G Will
Journal:  Histopathology       Date:  2000-07       Impact factor: 5.087

3.  Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease.

Authors:  Kaj Blennow; Annica Johansson; Henrik Zetterberg
Journal:  Int J Mol Med       Date:  2005-12       Impact factor: 4.101

4.  CSF detection of the 14-3-3 protein in unselected patients with dementia.

Authors:  P R Burkhard; J C Sanchez ; T Landis; D F Hochstrasser
Journal:  Neurology       Date:  2001-06-12       Impact factor: 9.910

5.  CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease.

Authors:  P Sanchez-Juan; A Green; A Ladogana; N Cuadrado-Corrales; R Sáanchez-Valle; E Mitrováa; K Stoeck; T Sklaviadis; J Kulczycki; K Hess; M Bodemer; D Slivarichová; A Saiz; M Calero; L Ingrosso; R Knight; A C J W Janssens; C M van Duijn; I Zerr
Journal:  Neurology       Date:  2006-08-22       Impact factor: 9.910

6.  Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?

Authors:  E Kapaki; K Kilidireas; G P Paraskevas; M Michalopoulou; E Patsouris
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-09       Impact factor: 10.154

Review 7.  Cerebrospinal fluid biomarkers in Creutzfeldt-Jakob disease.

Authors:  B Van Everbroeck; J Boons; P Cras
Journal:  Clin Neurol Neurosurg       Date:  2005-01-12       Impact factor: 1.876

8.  The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies.

Authors:  P Amouyel; O Vidal; J M Launay; J L Laplanche
Journal:  Lancet       Date:  1994-11-12       Impact factor: 79.321

9.  Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease.

Authors:  Michael D Geschwind; Jennifer Martindale; Deborah Miller; Stephen J DeArmond; Jane Uyehara-Lock; David Gaskin; Joel H Kramer; Nicholas M Barbaro; Bruce L Miller
Journal:  Arch Neurol       Date:  2003-06

10.  Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease.

Authors:  I Zerr; M Bodemer; S Räcker; S Grosche; S Poser; H A Kretzschmar; T Weber
Journal:  Lancet       Date:  1995-06-24       Impact factor: 79.321

View more
  16 in total

1.  Characteristics of Korean patients with suspected Creutzfeldt-Jakob disease with 14-3-3 protein in cerebrospinal fluid: Preliminary study of the Korean Creutzfeldt-Jakob disease active surveillance program.

Authors:  Jae-Sung Lim; Hyung-Min Kwon; Jae-Won Jang; Young-Ran Ju; SuYeon Kim; Young Ho Park; So Young Park; SangYun Kim
Journal:  Prion       Date:  2015       Impact factor: 3.931

Review 2.  Interpretation of cerebrospinal fluid protein tests in the diagnosis of sporadic Creutzfeldt-Jakob disease: an evidence-based approach.

Authors:  Michael B Coulthart; Gerard H Jansen; Neil R Cashman
Journal:  CMAJ       Date:  2014-01-20       Impact factor: 8.262

3.  CSF Tau proteins reduce misdiagnosis of sporadic Creutzfeldt-Jakob disease suspected cases with inconclusive 14-3-3 result.

Authors:  M J Leitão; I Baldeiras; M R Almeida; M H Ribeiro; A C Santos; M Ribeiro; J Tomás; S Rocha; I Santana; C R Oliveira
Journal:  J Neurol       Date:  2016-06-29       Impact factor: 4.849

4.  Comparing CSF biomarkers and brain MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease.

Authors:  Sven A Forner; Leonel T Takada; Brianne M Bettcher; Iryna V Lobach; Maria Carmela Tartaglia; Charles Torres-Chae; Aissatou Haman; Julie Thai; Paolo Vitali; John Neuhaus; Alan Bostrom; Bruce L Miller; Howard J Rosen; Michael D Geschwind
Journal:  Neurol Clin Pract       Date:  2015-04

5.  Cerebrospinal Fluid Biomarkers in the Diagnosis of Creutzfeldt-Jakob Disease in Slovak Patients: over 10-Year Period Review.

Authors:  Silvia Koscova; Dana Zakova Slivarichova; Ivana Tomeckova; Katarina Melicherova; Martin Stelzer; Alzbeta Janakova; Dana Kosorinova; Girma Belay; Eva Mitrova
Journal:  Mol Neurobiol       Date:  2016-09-24       Impact factor: 5.590

6.  Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic.

Authors:  Matthias Schmitz; Elisabeth Ebert; Katharina Stoeck; André Karch; Steven Collins; Miguel Calero; Theodor Sklaviadis; Jean-Louis Laplanche; Ewa Golanska; Ines Baldeiras; Katsuya Satoh; Raquel Sanchez-Valle; Anna Ladogana; Anders Skinningsrud; Anna-Lena Hammarin; Eva Mitrova; Franc Llorens; Yong Sun Kim; Alison Green; Inga Zerr
Journal:  Mol Neurobiol       Date:  2015-05-07       Impact factor: 5.590

Review 7.  Clinical Use of Improved Diagnostic Testing for Detection of Prion Disease.

Authors:  Mark P Figgie; Brian S Appleby
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

8.  Decreased CSF transferrin in sCJD: a potential pre-mortem diagnostic test for prion disorders.

Authors:  Ajay Singh; Alim J Beveridge; Neena Singh
Journal:  PLoS One       Date:  2011-03-09       Impact factor: 3.240

9.  Cerebrospinal fluid markers in sporadic Creutzfeldt-Jakob disease.

Authors:  Gianluigi Zanusso; Michele Fiorini; Sergio Ferrari; Alberto Gajofatto; Annachiara Cagnin; Andrea Galassi; Silvia Richelli; Salvatore Monaco
Journal:  Int J Mol Sci       Date:  2011-09-23       Impact factor: 5.923

10.  Chinese specific characteristics of sporadic Creutzfeldt-Jakob disease: a retrospective analysis of 57 cases.

Authors:  Wei Zhao; Jia-Tang Zhang; Xiao-Wei Xing; De-Hui Huang; Cheng-Lin Tian; Wei-Quan Jia; Xu-Sheng Huang; Wei-Ping Wu; Chuan-Qiang Pu; Sen-Yang Lang; Sheng-Yuan Yu
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.